SCHEMBL21473723

SCHEMBL21473723

COC1COc2cc3c(cc2OC1)-c1cc(=O)c(C(=O)O)cn1CC3

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.34
CYP2D6 P10635 1/20 0.32
CYP2B6 P20813 1/20 0.30
TENT4A Q5XG87 1/20 0.30
TENT4B Q8NDF8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21473824 0.91 BCHE (0.33) BCHECYP2D6
SCHEMBL21473844 0.88 CYP2D6 (0.33) BCHECYP2D6
SCHEMBL10933871 0.85 CYP2D6 (0.41) BCHECYP2D6
SCHEMBL22355603 0.83 SMN1; SMN2 (0.41) CYP2D6
SCHEMBL29714639 0.80 CYP2B6 (0.33) CYP2B6TENT4ATENT4B
SCHEMBL21327081 0.80 CYP2B6 (0.33) CYP2B6TENT4ATENT4B
SCHEMBL21473823 0.78 KCNK3 (0.37) BCHECYP2D6
SCHEMBL21475485 0.77 CYP2B6 (0.35) CYP2B6TENT4ATENT4B
SCHEMBL17266002 0.76 ACHE (0.40)
SCHEMBL21066238 0.75 CYP2B6 (0.35) CYP2B6TENT4ATENT4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11013726-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-25 US disclosed
US-10821103-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2020-11-03 US disclosed
US-20200261432-A1 SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2020-08-20 US disclosed
US-20190314347-A1 SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200261432-A1 SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME HAVCR2, HCCS, TYMP BCHE 709/4885CYP2D6 94/4885CYP2B6 12/4885
US-20190314347-A1 SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME HAVCR2, HCCS, TYMP BCHE 709/4885CYP2D6 94/4885CYP2B6 12/4885
US-11013726-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same HAVCR2, HCCS, TYMP BCHE 709/4885CYP2D6 94/4885CYP2B6 12/4885
US-10821103-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same HAVCR2, HCCS, TYMP BCHE 709/4885CYP2D6 94/4885CYP2B6 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.